A strategic collaboration to construct the most powerful pharmaceutical-owned supercomputer was announced by Eli Lilly and Company (Lilly) and NVIDIA, with the goal of supercharging the entire drug lifecycle from discovery to delivery.

This system will function as an "AI factory," a specialized computing infrastructure that manages the entire AI workflow, from data ingestion and model training to high-volume inference, allowing scientists to rapidly learn and iterate. Leveraging decades of proprietary data, the supercomputer—which is the world’s first NVIDIA DGX SuperPOD with DGX B300 systems, featuring over 1,000 B300 GPUs—will empower researchers to train advanced AI models on millions of experiments to identify, optimize, and validate new molecules, dramatically expanding the scope of drug discovery efforts.

Furthermore, Lilly plans to utilize the supercomputer beyond discovery to shorten development cycles, with new applications including the use of scientific AI agents for reasoning and planning, advanced medical imaging to develop personalized biomarkers, and the implementation of digital twins with NVIDIA robotics to enhance manufacturing efficiency and reduce downtime. Lilly views this initiative as a profound shift toward embracing AI as a "scientific collaborator," positioning the company at the forefront of the AI industrial revolution in medicine to accelerate innovation and deliver life-changing medicines to patients faster, all while operating the system on 100% renewable electricity in line with its sustainability commitments.